Third-Quarter 2023 Business Review

Marcy l’Étoile, October 26, 2023 – bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the nine months ended September 30, 2023.

• +8.0% sales organic growth over the first nine months of the year: €2,668 million in sales ; +4% as reported
• Q3 sales organic growth at +7.1% (+10.3% excluding BIOFIRE® respiratory panels), on par with expectations 
• BIOFIRE® non-respiratory panels grew by +24% in Q3 thanks to successful cross-selling by leveraging the large BIOFIRE® installed base and the broadest menu in the market 
• Remarkable resilience of the BIOFIRE® respiratory panels sales (-2% over the 9 months period, -5% in Q3) in a 2023 post COVID environment, demonstrating the value of the syndromic solution 
• Strong momentum in clinical microbiology (+11% in Q3) thanks to the continued uptake of the VITEK® MS PRIME and the relevance of the product portfolio to support the fight against Antimicrobial Resistance 
• Promising launch of BIOFIRE® SPOTFIRE® with close to 400 installed instruments at the end of September 2023 and high customers interest. On-going geographical expansion out of the US with the start in Japan, and broadening of the menu through the FDA filing of the BIOFIRE® SPOTFIRE® Respiratory Sore Throat panel in October
• Confirmation of the 2023 guidance: Organic sales growth between +4 and +6% ; Contributive operating income before non-recurring items should be in a range of €600 million to €630 milllion

Pierre Boulud, Chief Executive Officer, said: “bioMérieux delivered a solid performance during the third quarter of 2023. The BIOFIRE® non-respiratory panels kept on growing at a very strong pace while respiratory panels sales were resilient. In addition, the microbiology franchise performed very well, driven by both volumes and prices increases. We expect BIOFIRE® respiratory panels sales to be lower in Q4 2023 than in Q4 2022, inflated by the triple-demic, but we are confident to achieve our full year targets.”